This study is in progress, not accepting new patients
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
Summary
- Eligibility
- for people ages 50 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by Michael S. Ip, MD (ucla)

Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Michael S. Ip, MD (ucla)
Dr. Michael S. Ip holds the Gavin S. Herbert Endowed Chair for Macular Degeneration.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Ocular Therapeutix, Inc.
- ID
- NCT06223958
- Phase
- Phase 3 Macular Degeneration Research Study
- Study Type
- Interventional
- Participants
- About 344 people participating
- Last Updated